2seventy bio (TSVT) Expected to Announce Quarterly Earnings on Tuesday

2seventy bio (NASDAQ:TSVT - Get Free Report) is projected to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect 2seventy bio to post earnings of ($0.20) per share and revenue of $12.84 million for the quarter.

2seventy bio Stock Performance

Shares of NASDAQ:TSVT traded up $0.14 during trading on Friday, hitting $2.64. 308,101 shares of the stock were exchanged, compared to its average volume of 293,203. The company has a market capitalization of $136.19 million, a price-to-earnings ratio of -1.42 and a beta of 1.74. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $5.99. The company's fifty day simple moving average is $2.65 and its 200-day simple moving average is $3.78.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of 2seventy bio in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $7.20.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.